Document Detail


Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders.
MedLine Citation:
PMID:  8813484     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Major pancreatic resection is still accompanied by considerable morbidity (35%) and mortality (10%). Typical complications, such as pancreatic fistula and abscess, are chiefly associated with exocrine pancreatic secretion. The hormone somatostatin and its analogue octreotide are well known as potent inhibitors of exocrine pancreatic secretion. In two randomised, double-blind, placebo-controlled, multicentre trials we assessed the prophylactic effect of the perioperative inhibition of exocrine pancreatic secretion by octreotide to prevent postoperative complications. Each patient received 3 X 100 micrograms/day octreotide or placebo subcutaneously. A significant reduction in fistula, abscess, fluid collection, sepsis and postoperative pancreatitis occurred with patients undergoing pancreatic resection for cancer. Results were similar in a second study, using the same protocol but recruiting only patients with chronic pancreatitis. A new randomised, controlled multicentre trial is also described, in which 300 patients with severe acute pancreatitis are being treated with or without octreotide in double-blind fashion. The results will clarify the influence of inhibition of exocrine pancreatic secretion by octreotide on the course of acute pancreatitis, and hence its potential, through inhibition of digestive enzyme secretion, as a treatment for acute pancreatitis.
Authors:
H Friess; M W Büchler
Related Documents :
24048334 - Labhardt's colpoperineocleisis: subjective results of an alternative treatment for geni...
23772334 - Experience with 25 years of dorsal root entry zone lesioning at a single institution.
14985844 - A comparison of two surgical strategies for the emergency treatment of gallstone ileus.
11768814 - Advanced age does not contribute to increased risks or poor outcome after major abdomin...
23413494 - Efficacy of two compression systems in the management of vlus: results of a european rct.
16422854 - Testosterone therapy can enhance erectile function response to sildenafil in patients w...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Digestion     Volume:  57 Suppl 1     ISSN:  0012-2823     ISO Abbreviation:  Digestion     Publication Date:  1996  
Date Detail:
Created Date:  1997-01-14     Completed Date:  1997-01-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0150472     Medline TA:  Digestion     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  97-102     Citation Subset:  IM    
Affiliation:
Department of Visceral and Transplantation Surgery, University of Bern, Inselspital, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal / therapeutic use*
Chronic Disease
Double-Blind Method
Female
Gastrointestinal Agents / therapeutic use*
Hormone Antagonists / therapeutic use*
Humans
Male
Middle Aged
Octreotide / therapeutic use*
Pancreas / surgery*
Pancreatic Diseases / drug therapy,  surgery,  therapy*
Pancreatic Neoplasms / complications,  drug therapy,  ultrasonography
Pancreatitis / drug therapy,  surgery,  therapy
Postoperative Complications / prevention & control
Prospective Studies
Somatostatin / analogs & derivatives*,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Gastrointestinal Agents; 0/Hormone Antagonists; 51110-01-1/Somatostatin; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Somatostatin analogues and pancreatic fistulas.
Next Document:  Pharmacological treatment of portal hypertension.